Rethinking Clinical Trials Reform During the COVID-19 Pandemic

JAMA Oncol. 2020 Sep 1;6(9):1327-1329. doi: 10.1001/jamaoncol.2020.3142.

Authors

Chadi Nabhan^{1

2}, Toni K Choueiri³, Anthony R Mato⁴

Affiliations

¹ Caris Life Sciences, Precision Oncology Alliance, Irving, Texas.
² Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia.
³ Dana-Farber Cancer Institute, Boston, Massachusetts.
⁴ Memorial Sloan Kettering Cancer Center, New York, New York.

PMID: 32761101
DOI: 10.1001/jamaoncol.2020.3142

No abstract available

MeSH terms

Betacoronavirus / pathogenicity
COVID-19
Clinical Trials as Topic
Coronavirus Infections / complications
Coronavirus Infections / epidemiology*
Coronavirus Infections / virology
Humans
Medical Oncology / trends
Neoplasms / complications
Neoplasms / epidemiology*
Neoplasms / virology
Pandemics*
Pneumonia, Viral / complications
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / virology
SARS-CoV-2